RETRACTED: Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies

Navid Shomali; Navid Shomali; Navid Shomali; Marwah Suliman Maashi; Behzad Baradaran; Behzad Baradaran; Amin Daei Sorkhabi; Aila Sarkesh; Hamed Mohammadi; Hamed Mohammadi; Maryam Hemmatzadeh; Faroogh Marofi; Siamak Sandoghchian Shotorbani; Siamak Sandoghchian Shotorbani; Mostafa Jarahian

doi:10.3389/fimmu.2022.839945

Frontiers in Immunology (Mar 2022)

RETRACTED: Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies

Navid Shomali,
Navid Shomali,
Navid Shomali,
Marwah Suliman Maashi,
Behzad Baradaran,
Behzad Baradaran,
Amin Daei Sorkhabi,
Aila Sarkesh,
Hamed Mohammadi,
Hamed Mohammadi,
Maryam Hemmatzadeh,
Faroogh Marofi,
Siamak Sandoghchian Shotorbani,
Siamak Sandoghchian Shotorbani,
Mostafa Jarahian

Affiliations

Navid Shomali: Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Navid Shomali: Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Navid Shomali: Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
Marwah Suliman Maashi: Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
Behzad Baradaran: Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Behzad Baradaran: Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Amin Daei Sorkhabi: Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
Aila Sarkesh: Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
Hamed Mohammadi: Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran
Hamed Mohammadi: Department of Immunology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
Maryam Hemmatzadeh: Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Faroogh Marofi: Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Siamak Sandoghchian Shotorbani: Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Siamak Sandoghchian Shotorbani: Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Mostafa Jarahian: German Cancer Research Center, Toxicology and Chemotherapy Unit (G401), Heidelberg, Germany

DOI: https://doi.org/10.3389/fimmu.2022.839945
Journal volume & issue: Vol. 13

Abstract

Read online

It has been well established that the etiopathogenesis of diverse autoimmune diseases is rooted in the autoreactive immune cells’ excessively proliferative state and impaired apoptotic machinery. Survivin is an anti-apoptotic and mitotic factor that has sparked a considerable research interest in this field. Survivin overexpression has been shown to contribute significantly to the development of autoimmune diseases via autoreactive immune cell overproliferation and apoptotic dysregulation. Several microRNAs (miRNAs/miRs) have been discovered to be involved in survivin regulation, rendering the survivin-miRNA axis a perspective target for autoimmune disease therapy. In this review, we discuss the role of survivin as an immune regulator and a highly implicated protein in the pathogenesis of autoimmune diseases, the significance of survivin-targeting miRNAs in autoimmunity, and the feasibility of targeting the survivin-miRNA axis as a promising therapeutic option for autoimmune diseases.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords